Menus Subscribe Search

Follow us


vaccine-diplomacy

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Next Steps in U.S.-Iran Diplomacy: Vaccines

• November 06, 2013 • 11:00 AM

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Two vaccine scientists—one American, one Iranian—offer a unique way to give the nascent relationship between their two countries a shot in the arm.

September’s historic dialogue between President Obama and Iran’s President Rouhani together with calls to seek constructive engagement opens the door to a little known but powerful foreign policy instrument, which could simultaneously create new life-saving vaccines.

The cornerstone of vaccine diplomacy is two or more countries putting aside their ideological differences to engage in an intense and focused scientific collaboration and produce an urgently needed technology that serves humanity.

In modern times, the first triumph of vaccine diplomacy occurred in the decade that began following the death of Stalin in 1953. Together, Dr. Albert B. Sabin in the U.S. and his Soviet virology counterpart each received back channel permission to jointly develop and then test a prototype oral polio vaccine on more than 10 million children in the USSR. The successful results led to the licensure of the oral polio vaccine in 1962, the elimination of polio in the U.S. in 1979, and ultimately the eradication of polio in all but three countries. Similar international cooperation with the Soviets to improve the vaccine was a key step resulting in the global eradication of smallpox.

Both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change.

Today, both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change. They include dengue fever, a mosquito-transmitted viral infection that results in hemorrhage, shock, and death. Dengue has recently emerged on the U.S. Gulf Coast and in southeastern Iran neighboring Pakistan. Kinetoplastid infections such as Chagas disease, a cause of severe heart disease, are now widespread among the poor in Texas and the southern U.S. where over 300,000 cases occur, while leishmaniasis, a severely disfiguring skin disease, affects 100,000 or more Iranians, and has also emerged in Texas and Oklahoma. Worm infections are still commonly found in impoverished areas in both countries, and where infections overall account for a significant amount of the health care burdens.

Both the U.S. and Iran would benefit enormously from research leading to the development and joint testing of vaccines against these neglected tropical diseases. Our recent investigations reveal that the extreme poor living in middle income and wealthy countries suffer as much from these conditions as those in the poorest countries in Africa, so that all of the world’s people living in poverty would benefit from new vaccines. Unfortunately because there is no major commercial market for neglected tropical disease vaccines (with the exception of dengue) the multinational pharmaceutical companies are not attempting to produce them.

In Iran, both fundamental and epidemiological research is conducted on a number of neglected tropical diseases including Crimean-Congo hemorrhagic fever, West Nile virus infection, brucellosis, leptospirosis, echinococcosis, fascioliasis, and intestinal worms. Iranian scientists have made several attempts at vaccines for some of their tropical infections, including prototype leishmaniasis vaccines made from live or killed whole parasites. However the efficacy and safety of such vaccines has thwarted further development along those lines. Nascent efforts to develop a safer and more effective vaccine through advanced genetic engineering—so called recombinant vaccines—are beginning, but a U.S. collaboration to accelerate their development will be needed. In addition, in order to enhance the efficacy of a recombinant leishmaniasis vaccine there may be requirements to add novel substances that increase the body’s immune response, but the best of these immunostimulants are currently only available in the West and can’t easily (or possibly legally) be shipped to Iran. Ultimately such steps would help to ensure future success in terms of producing a vaccine that would be widely used in the Middle East and adjoining regions of North Africa and Central Asia.

Indeed, such vaccines could be developed in the non-profit sector through joint activities of U.S.-based product development partnerships through support of the Gates Foundation, the National Institutes of Health, and other sources, together with Iranian institutions, such as the Tehran University and the Razi Serum and Vaccine Institute. However, meaningful scientific collaboration to actually produce such products is not currently practical given both financial and political constraints, including the need to overcome fears of potentially producing so-called “dual use” technologies. Therefore, high-level discussions need to first take place between the U.S. Department of State and its Iranian counterpart to actively encourage and support joint vaccine development, and then implement steps to effectively shape policy and launch the first stages of vaccine product development, including antigen discovery, process development, pilot manufacture, regulatory filing, and initial clinical testing.

Vaccine diplomacy’s modern day track record is impressive, having led to the global eradication of smallpox and the near-elimination of polio. It occurred because the U.S. and USSR put aside their differences during the Cold War. We now have an opening and potential path to do the same between the U.S. and Iran.

Peter Hotez and Mohammad Rokni
Peter Hotez is president of the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development; dean of the National School of Tropical Medicine, Baylor College of Medicine; and Baker Institute Fellow in Disease and Poverty. Mohammad B. Rokni is professor of Medical Parasitology and Mycology in the School of Public Health at the Tehran University of Medical Sciences.

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 30 • 8:00 AM

How Do You Make a Living, Email Newsletter Writer?

Noah Davis talks to Wait But Why writer Tim Urban about the newsletter concept, the research process, and escaping “money-flushing toilet” status.



October 30 • 6:00 AM

Dreamers of the Carbon-Free Dream

Can California go full-renewable?


October 30 • 5:08 AM

We’re Not So Great at Rejecting Each Other

And it’s probably something we should work on.


October 30 • 4:00 AM

He’s Definitely a Liberal—Just Check Out His Brain Scan

New research finds political ideology can be easily determined by examining how one’s brain reacts to disgusting images.


October 29 • 4:00 PM

Should We Prosecute Climate Change Protesters Who Break the Law?

A conversation with Bristol County, Massachusetts, District Attorney Sam Sutter, who dropped steep charges against two climate change protesters.


October 29 • 2:23 PM

Innovation Geography: The Beginning of the End for Silicon Valley

Will a lack of affordable housing hinder the growth of creative start-ups?


October 29 • 2:00 PM

Trapped in the Tobacco Debt Trap

A refinance of Niagara County, New York’s tobacco bonds was good news—but for investors, not taxpayers.


October 29 • 12:00 PM

Purity and Self-Mutilation in Thailand

During the nine-day Phuket Vegetarian Festival, a group of chosen ones known as the mah song torture themselves in order to redirect bad luck and misfortune away from their communities and ensure a year of prosperity.


October 29 • 10:00 AM

Can Proposition 47 Solve California’s Problem With Mass Incarceration?

Reducing penalties for low-level felonies could be the next step in rolling back draconian sentencing laws and addressing the criminal justice system’s long legacy of racism.


October 29 • 9:00 AM

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.


October 29 • 8:00 AM

America’s Bathrooms Are a Total Failure

No matter which American bathroom is crowned in this year’s America’s Best Restroom contest, it will still have a host of terrible flaws.



October 29 • 6:00 AM

Tell Us What You Really Think

In politics, are we always just looking out for No. 1?


October 29 • 4:00 AM

Racial Resentment Drives Tea Party Membership

New research finds a strong link between tea party membership and anti-black feelings.


October 28 • 4:00 PM

The New Health App on Apple’s iOS 8 Is Literally Dangerous

Design isn’t neutral. Design is a picture of inequality, of systems of power, and domination both subtle and not. Apple should know that.


October 28 • 2:00 PM

And You Thought Your Credit Card Debt Was Bad

In Niagara County, New York, leaders took on 40-year debt to pay for short-term stuff, a case study in the perverse incentives tobacco bonds create.



October 28 • 10:00 AM

How Valuable Is It to Cure a Disease?

It depends on the disease—for some, breast cancer and AIDS for example, non-curative therapy that can extend life a little or a lot is considered invaluable. For hepatitis C, it seems that society and the insurance industry have decided that curative therapy simply costs too much.


October 28 • 8:00 AM

Can We Read Our Way Out of Sadness?

How books can help save lives.



October 28 • 6:15 AM

Incumbents, Pray for Rain

Come next Tuesday, rain could push voters toward safer, more predictable candidates.


October 28 • 6:00 AM

Why Women Are Such a Minority in Elected Office

The obvious answers aren’t necessarily the most accurate. Here, five studies help clear up the gender disparity in politics.


October 28 • 4:00 AM

The Study of Science Leads to Leftward Leanings

Researchers report the scientific ethos tends to produce a mindset that favors liberal political positions.


October 28 • 2:00 AM

Who Funded That? The Names and Numbers Behind the Research in Our Latest Issue

This list includes studies cited in our pages that received funding from a source other than the researchers’ home institutions. Only principal or corresponding authors are listed.


Follow us


We’re Not So Great at Rejecting Each Other

And it's probably something we should work on.

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.

Incumbents, Pray for Rain

Come next Tuesday, rain could push voters toward safer, more predictable candidates.

Could Economics Benefit From Computer Science Thinking?

Computational complexity could offer new insight into old ideas in biology and, yes, even the dismal science.

Politicians Really Aren’t Better Decision Makers

Politicians took part in a classic choice experiment but failed to do better than the rest of us.

The Big One

One town, Champlain, New York, was the source of nearly half the scams targeting small businesses in the United States last year. November/December 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.